Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Baseline characteristics of study population of new users and non-users of statins

Values are numbers (percentages) unless stated otherwise

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Crude incidence per 10 000 person years for study outcomes in both men and women

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Risk associated with statin type both in men and in women for non-significant and marginal outcomes

Hip

pisl

ey-C

ox J

, C

oupl

and

C.

B

MJ

2010

;340

:c21

97

Risk of significant outcomes associated with type and dose of statin both in men and in women - Part I

Hip

pisl

ey-C

ox J

, C

oupl

and

C.

B

MJ

2010

;340

:c21

97

Risk of significant outcomes associated with type and dose of statin both in men and in women - Part II

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Relative incidence rate ratios from case series analysis for men and women combined for

significant outcomes associated with statin type

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases for each outcome over five years in patients aged 35-74

free of cardiovascular disease at baseline with QRISK2 score of ≥20% or ≥15%

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197